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The conversion of somatic cells into pluripotent stem cells via overexpression of reprogramming factors involves
epigenetic remodeling. DNA methylation at a significant proportion of CpG sites in induced pluripotent stem cells
(iPSCs) differs from that of embryonic stem cells (ESCs). Whether different sets of reprogramming factors influence
the type and extent of aberrant DNA methylation in iPSCs differently remains unknown. In order to help resolve
this critical question, we generated human iPSCs from a common fibroblast cell source using either the Yamanaka
factors (OCT4, SOX2, KLF4 and cMYC) or the Thomson factors (OCT4, SOX2, NANOG and LIN28), and determined
their genome-wide DNA methylation profiles. In addition to shared DNA methylation aberrations present in all our
iPSCs, we identified Yamanaka-iPSC (Y-iPSC)-specific and Thomson-iPSC (T-iPSC)-specific recurrent aberrations.
Strikingly, not only were the genomic locations of the aberrations different but also their types: reprogramming
with Yamanaka factors mainly resulted in failure to demethylate CpGs, whereas reprogramming with Thomson
factors mainly resulted in failure to methylate CpGs. Differences in the level of transcripts encoding DNMT3b and
TET3 between Y-iPSCs and T-iPSCs may contribute partially to the distinct types of aberrations. Finally, de novo
aberrantly methylated genes in Y-iPSCs were enriched for NANOG targets that are also aberrantly methylated in
some cancers. Our study thus reveals that the choice of reprogramming factors influences the amount, location,
and class of DNA methylation aberrations in iPSCs. These findings may provide clues into how to produce human
iPSCs with fewer DNA methylation abnormalities.Introduction
Ectopic expression of transcription factors highly expressed
in ESCs can reprogram somatic cells into pluripotent
stem cells [1]. The discovery of this method has gener-
ated great excitement because it can potentially pro-
vide a patient-specific cell source for cell replacement
therapy and can be used to model genetic diseases for
drug discovery [2]. iPSCs have now been generated from
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unless otherwise stated.have been identified that increase reprogramming effi-
ciency [3].
Induction of pluripotency by reprogramming factors
is accompanied by extensive epigenetic changes in the
reprogramming factor recipient cells [4-7]. Methylation
of DNA at CpG dinucleotide plays an important role in
regulating gene transcription and silencing transpo-
sons. Trichostatin A (a histone deacetylase inhibitor)
and 5-Azacytidine (a DNA methylation inhibitor) in-
crease reprogramming efficiency suggesting that the
resistance of somatic cell chromatin to remodeling is a
barrier to reprogramming [4,5,8]. Many regions in the
genome might have a chromatin state such as hetero-
chromatin that is recalcitrant to remodeling by repro-
gramming factors. Indeed, a recent study identifiedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gions flanking centromeres and telomeres were enriched
for aberrations [9]. DNA methylation failure at genes spe-
cifically expressed in differentiated cells is a well-described
type of aberrations present in iPSCs. These aberrations re-
sult in expression of differentiated genes in iPSCs that can
negatively affect the propensity differentiation into various
lineages [10-13]. Furthermore, DNA methylation aberra-
tions have been shown to persist during passaging [11]
and differentiation [14,15]. Consequently, a key concern in
the field is that epigenetic aberrations in iPSCs may limit
their use in regenerative medicine, disease modeling and
drug discovery.
Though new reprogramming factors and combinations
have been found, the two most commonly used now-
adays are the Yamanaka factors (OCT4, SOX2, KLF4
and cMYC) and the Thomson factors (OCT4, SOX2,
NANOG and LIN28). However, the majority of studies
have mainly profiled iPSCs derived using a single type of
reprogramming factor cocktail (i.e. the Yamanaka factors).
It is difficult to compare the genome-wide DNA methyla-
tion profiles of iPSCs derived using Yamanaka factors
against iPSCs (Y-iPSCs) derived using Thomson factors
(T-iPSCs) from different studies, since the tissue of origin
are different or come from different individuals in each
study. Thus it is unknown whether the choice of repro-
gramming factors influences the extent and the type of
DNA methylation aberrations in iPSCs.
In this study, we assessed genome-wide DNA methy-
lation profiles of 15 iPSCs lines made with Yamanaka
[16,17] and Thomson [18] reprogramming factors from
a common batch of fibroblasts using the Illumina Human-
Methylation450 platform. In agreement with previous
studies [10-13,15] we have found significant levels of
recurrent aberrations present in all iPSCs. In addition,
we observed DNA methylation aberrations specific for
Y-iPSCs and T-iPSCs despite being derived from the same
parental cells and undergoing the same conditions and
duration in culture. The key finding of our paper is that
DNA methylation aberrations in Y-iPSCs are largely due
to failure to erase parental methylation while the aber-
rations in T-iPSCs are largely due to the failure to place
ESC specific methylation marks.
Results
Genome wide DNA methylation profiles reveal
aberrations in iPSCs
iPSCs were derived from human neonatal foreskin fibro-
blasts via retroviral infection of reprogramming factors
[16,17]. A common batch of human neonatal foreskin
fibroblasts was split into 3 groups (Figure 1A). The first
set was directly processed for DNA methylation analysis.
The second set was infected with retroviruses encoding
the Yamanaka factors, i.e. OCT4, SOX2, KLF4 and cMYCreprogramming factors. The third set was infected with
retroviruses encoding the Thomson factors, i.e. OCT4,
SOX2, NANOG and LIN28 reprogramming factors.
We selected 9 Y-iPSCs and 6 T-iPSCs that had charac-
teristic ESC-like morphology, express several pluripo-
tency genes and can be stably maintained in culture
(Figure 1A; Additional file 1: Figure S1). Genomic DNA
from each of the iPSCs was subjected to DNA methy-
lation profiling using the Illumina HumanMethy-
lation450 platform. We augmented our data set with
published Illumina HumanMethylation450 methylation
data for several male ESCs (SIVF002, SIVF025, SIVF043,
SIVF044, SIVF050) [14]. To validate the DNA methylation
data obtained by the Illumina HumanMethylation450 plat-
form we performed high throughput sequencing based
DNA methylation assessment called reduced representa-
tion bisulfite sequencing (RRBS) in one of the Y-iPSCs and
one of the T-iPSCs. The overall methylation data from
Illumina HumanMethylation450 and RRBS data were con-
cordant (with an average correlation coefficient of 0.8)
(Additional file 1: Figure S2). These results are very
similar to the Pearson correlation between RRBS and
Illumina’s DNA methylation arrays obtained in a differ-
ent study using the same cutoffs [19] and argue in favor
of the reliability of the data obtained in our study.
To determine the concordance of methylation values
between parental fibroblast, iPSC and ESC samples, we
performed unsupervised consensus clustering [20] with
the computed pairwise correlation coefficient of all DNA
methylation values and identified 3 DNA methylation
clusters (Figure 1B). Cluster 1 formed a particularly tight
cluster well separated from the other 2 clusters and was
composed by the parental fibroblasts. iPSCs and ESCs
comprised clusters 2 and 3, respectively (Figure 1B).
This shows that, as expected, the DNA methylomes of
iPSCs were distinct from the parental fibroblasts and
closer to, but segregated from, the methylomes of ESCs.
Fibroblasts had much higher proportion of lowly meth-
ylated CpGs than highly methylated CpGs; this trend
was opposite in ESCs and iPSCs (Figure 1C). We com-
puted the percentage of CpGs in fibroblasts and iPSCs
that are significantly different in methylation state from
those in ESCs. Fibroblasts had about 17% of the CpGs
that have significantly different levels of methylation
than in ESCs, while iPSCs had less than 2% of the CpGs
that are different from ESCs (Figure 1D). Interestingly,
in fibroblasts, hypermethylated CpGs were more likely to
have different methylation state from ESCs than hypo-
methylated states, while CpGs in iPSCs with methy-
lation values different from ESCs are equally likely to
be hypermethylated or hypomethylated (Figure 1D).
Finally, CpGs with methylation values significantly dif-
ferent between iPSCs and ESCs are enriched for those
that are hypomethylated in fibroblasts compared with
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Figure 1 Experimental design and comparison of DNA methylation profiles of iPSCs and ESCs. A) Scheme showing the experimental
design. Cells were treated identically and 25 days post-infection, colonies were picked randomly and maintained in culture for 6 passages. We
profiled DNA methylation during early passage iPSCs to reduce the confounding contribution of negative selection during culture conditions [32],
which may mask the differences between these 2 reprogramming factor combinations. B) Pair-wise plot shows that all iPSC methylomes are similar to
ESC methylomes and significantly different from fibroblast methylomes. The raw methylation data was normalized and background-subtracted using
the Illumina Genome Studio software. Intensity values were converted to beta-values where the value of 0 represents unmethylated and the value of 1
represents fully methylated. Fib stands for fibroblasts. C) Boxplot of the percentages of highly methylated (red) and lowly methylated (blue) CpGs in
fibroblasts, ESCs, Y-iPSCs and T-iPSCs show that their overall levels in iPSCs are largely similar to those in ESCs. Hypermethylated CpGs are
defined as those with values > 0.7 and hypomethylated CpGs are defined as those with values < 0.3. Hyper and Hypo stand for hypermethylated
and hypomethylated, respectively. D) Boxplot of the percentages of highly methylated (red) and lowly methylated (blue) CpGs in fibroblasts,
Y-iPSCs and T-iPSCs that are significantly different from ESCs (defined as those with difference in methylation > =0.2) show that only a small proportion
of the CpGs in iPSCs are different from those in ESCs. E) Boxplot made as in Figure 1D but restricted to only those CpGs that change their methylation
state from fibroblasts to ESCs. CpGs hypomethylated in fibroblasts but hypermethylated in ESCs (green) are more likely to be significantly different in
iPSCs than CpGs that are hypermethylated in fibroblasts and hypomethylated in ESCs (yellow).
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ated in iPSCs (Figure 1E). This result is consistent with
previous findings [3].
In order to identify the CpGs that are differentially
methylated between iPSCs and ESCs, we used a DNA
methylation difference of more than 0.2 or less than −0.2
and a False Discovery Rate (FDR)-corrected p-value lower
than 0.05 as a threshold (Additional file 1: Figure S3).
DNA methylation aberrations shared by iPSCs were parti-
tioned into 4 classes: Class I represented de novo methy-
lation (defined as methylated regions in iPSCs which are
unmethylated in ESCs and in parental cells), Class II rep-
resented failed methylation (defined as unmethylated
regions in iPSCs which are unmethylated in parental cells
but methylated in ESCs), Class III represented failed
demethylation (defined as methylated regions in iPSCs
which are methylated in parental cells but unmethylated
in ESCs); and Class IV represented de novo demethylation
(defined as unmethylated sites in iPSCs that are methyl-
ated in both parental cells and ESCs). Consistent with
previous findings, all the iPSCs had DNA methylation ab-
errations (Figure 2A-E). About 62% of the aberrations
were Class II (failed methylation) (Figure 2B) and about
32% of the aberrations were Class III (failed demethyla-
tion) (Figure 2D). These results suggest that inadequate
change of parental DNA methylation state (also referred
to as tissue of origin memory), rather than de novo
changes in DNA methylation, is the type of aberration
shared by all iPSCs regardless of whether the Yamanaka or
the Thomson reprogramming factors were used.
A recent study [15], which used a capture-based ap-
proach to characterize DNA methylation levels in 17 iPSCs
generated derived from several cell types using the Yama-
naka factors, identified 9 genes that they found to harbor
aberrant DNA methylation regardless of the parental
source used. We scrutinized the methylation values of
these 9 genes in our dataset and found that only 4 genes
(FAM19A5, CSMD1, TCERG1L and TMEM132D) were
aberrantly methylated in all the iPSC, while 2 others (DPP6and TMEM132C) were aberrantly methylated in T-iPSCs
only. The DNA methylation levels of the remaining 3 genes
(RBFOX1, C22ORF34 and PTPRT) did not show obvious
recurrent aberrant methylation (Figure 2F). The discrep-
ancy between their data and our results might be due to
differences in the reprogramming protocol, cell culture or
the donor cells.
Y-iPSC and T-iPSC-specific DNA methylation aberrations
are of different classes
Though previous studies have identified recurrent DNA
methylation alterations in iPSCs when compared to
ESCs, no systematic study has been done to determine
how the extent and type of DNA methylation aberra-
tions depend on the factors used for reprogramming.
Our study was specifically designed to identify these dif-
ferences. We performed a Principal Component Analysis
of global DNA methylation values, and observed that
though all the iPSCs are closer to ESCs than fibroblasts,
they separated in two distinct groups according to the re-
programming factors used to generate them (Figure 3A).
We identified 6,011 CpGs that were differentially meth-
ylated between T-iPSCs and Y-iPSCs (1,722 CpGs were
hypermethylated in T-iPSCs and 4,289 CpGs were
hypermethylated in Y-iPSCs) (Figure 3B; Additional file 2:
Table S1). Note that these are not a subset of aber-
rantly methylated CpGs found in all iPSCs (Figure 2).
Among these 6,011 CpGs we observed that in both
T-iPSCs and Y-iPSCs they corresponded to all 4 classes of
DNA methylation aberrations described above (Figure 3C
to G). Interestingly, both T-iPSCs and Y-iPSCs had fewer
de novo aberrations (Class I and IV) than expected by
chance (p < 0.001) and more failure aberrations (Class II
and III) than expected by chance (p < 0.001) (Additional
file 1: Figure S4). Moreover, T-iPSCs had substantially
more Class II and fewer Class III aberrations than Y-iPSCs
(Figure 3G and Additional file 1: Figure S4). Thus, Y-
iPSCs mainly suffer from demethylation failure while T-
iPSCs mainly suffer from methylation failure. We also
Figure 2 (See legend on next page.)
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Figure 2 DNA methylation aberrations that are common in Y- and T-iPSCs. A. Hypomethylated CpGs in fibroblasts that undergo de novo
methylation. B. Hypomethylated CpGs that fail to be methylated. C. Hypermethylated CpGs in fibroblasts that fail to be demethylated. D.
Hypermethylated CpGs in fibroblasts that get aberrantly methylated. E. Summary of the classes of DNA methylation aberrations found in all the
iPSCs. F. DNA methylation of CpGs at the transcription start site of 9 genes reported to be aberrantly methylated in all iPSCs [15].
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and demethylation) preferentially present at non-CpG
island regions in both Y-iPSCs and T-iPSCs, while fail-
ure aberrations (Class II and Class III) are enriched at
CpG islands or shores (Additional file 1: Figure S5).
Note that approximately 57% (3446 out of 6011 CpGs
identified in Figure 3B) of the CpGs that showed recurrent
differences between Y-iPSCs and T-iPSCs did not fall
into Class I or IV. Interestingly, aberrantly methylated
CpGs (Class I) in Y-iPSCs and T-iPSCs were enriched
at transcription start sites (TSS) (Additional file 1:
Figure S6).
Enrichment of aberrations at reprogramming factor-binding
regions suggests targeting as a potential cause of DNA
methylation aberrations in Y-iPSCs and T-iPSCs
Among other possibilities, differences in the classes of
aberrations in Y-iPSCs and T-iPSCs might be due to dif-
ferent levels of DNA methylation and demethylation
enzymes during reprogramming or it might be due to
different targeting of these enzymes to the genomic re-
gions containing the aberrations. To determine whether
the levels and the targeting of DNA methylation ma-
chinery may contribute to the observed aberrations, we
first tested whether the levels of DNA methylation and
demethylation enzymes are aberrant. We found that the
level of DNMT3b was lower in T-iPSCs than in ESCs or
Y-iPSCs, which may potentially contribute to the de novo
methylation defects in Y-iPSCs (Figure 4A). Moreover,
TET3 was higher in T-iPSCs than ESCs or Y-iPSCs and
may potentially contribute to excessive demethylation in
Y-iPSCs (Figure 4A).
To determine if the targeting of DNA methylation ma-
chinery to specific loci by the reprogramming factors
might contribute to the observed aberrations we ana-
lyzed the methylation defects at genes targeted by the
reprogramming factors. We analyzed published ChIP-
seq data and quantified the enrichment of aberrations at
regions bound by reprogramming factors in ESCs [21]
(Additional file 3: Table S2). We observed that CpGs
with an aberrant DNA methylation (Class I and II) in
Y-iPSCs are significantly (P = 2 x 10-27) enriched for the
NANOG binding sites in ESCs (Figure 4B). Moreover,
CpGs that are aberrantly methylated (Class I and II) in
T-iPSCs are significantly (P = 4 x 10-8) depleted at OCT4
bound regions (Figure 4C). The statistically significant
increase in aberrations in Y-iPSCs at CpGs within thegenomic regions bound by NANOG suggests that some
of the CpG aberrations might be a consequence of inad-
equate targeting of DNA methyltransferase or the DNA
demethylation machinery to CpG sites and may contrib-
ute to differences between the methylomes of Y-iPSCs
and T-iPSCs (Figures 1B and 3A). The list of all genes
whose TSS contain one or more aberrantly methylated
CpGs are provided in Table 1.
We used Genomic Regions Enrichment of Anno-
tations Tool [22] to determine enrichment of specific
classes of genes. Genomic regions with aberrant DNA
methylation patterns in Y-iPSCs are enriched for genes
with roles in stem cell maintenance (which are normally
hypermethylated in fibroblasts), while genomic regions
with aberrant DNA methylation patterns in T-iPSCs are
enriched for lineage specific genes (which are normally
hypomethylated in fibroblasts) (Table 2).
Relationship between DNA methylation aberrations in
iPSCs and DNA methylation aberration in cancer
One major concern related to use iPSCs for regenerative
medicine is the increased tumorigenicity of iPSCs. To gain
further insight into the differences in the type of DNA
methylation aberrations found in Y-iPSCs or T-iPSCs, we
tested whether the differentially methylated CpGs are also
aberrantly methylated in cancers. We obtained publicly
available DNA methylation data generated by The Cancer
Genome Atlas consortium [23]. We evaluated the DNA
methylation difference (delta beta value) between cancer
patients and matched normal tissue of each CpG site
identified as aberrantly methylated in Y-iPSCs (Figure 5,
left panels) or T-iPSCs (Figure 5, right panels). We ana-
lyzed 6 cancer types: bladder urothelial carcinoma
(Additional file 1: Figure S7), breast invasive carcinoma
(Additional file 1: Figure S7), colon adenocarcinoma
(Figure 5A), head and neck squamous cell carcinoma
(Figure 5B), lung adenocarcinoma (Additional file 1:
figure S7), lung squamous cell carcinoma (Additional
file 1: Figure S7). We observed that CpG sites that
exhibited Class I aberrations in T-iPSCs were enriched
(P < 0.05) among Class I aberrations in colon adenocar-
cinoma and head and neck squamous cell carcinoma
(Figure 5). It is not obvious if genes present within the
regions proximal to Class I aberrations shared between
T-iPSCs and the 2 cancers play a functional role or
have features that would make them susceptible to
spurious methylation.
Figure 3 (See legend on next page.)
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Figure 3 DNA methylation aberrations that are found only in Y- or T-iPSCs. A. Principal Component Analysis showing that methylomes of
Y-iPSCs, T-iPSCs and ESCs segregate into separate groups. B. Volcano plots of all CpG sites analyzed. The beta value difference in DNA methylation
between Y-iPSCs and T-iPSCs is plotted on the x-axis, and the p-value for a FDR-corrected Wilcoxon signed-rank test of differences between
Y-iPSCs and T-iPSCs (shown on − log10 scale) is plotted on the y-axis. CpGs that are significantly different between the 2 subtypes are shown on
the upper left corner (significantly hypermethylated in T-iPSCs) and upper right corner (significantly hypermethylated in Y-iPSCs). C. CpGs that
are hypomethylated in fibroblasts but are aberrantly methylated in iPSCs. D. CpGs that are hypomethylated in fibroblasts but fail to acquire
methylation in iPSCs. E. CpGs that are hypermethylated in fibroblasts but aberrantly demethylated. F. CpGs that hypermethylated in fibroblasts
but aberrantly gets demethylated in iPSCs. G. Summary of the classes of DNA methylation aberrations found only in Y-iPSCs (left) or T-iPSCs (right)
but not both.
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The determinants and the temporal order of epigenetic
changes during reprogramming to pluripotency are poorly
understood. It is clear that to acquire pluripotency, rep-
rogramming cells must erase differentiation-specific epi-
genetic marks to return to the state that defines the
uncommitted pluripotent embryonic stem cell state [24].A
B C
Figure 4 Levels of DNA methylation and demethylation enzymes and
sites of reprogramming factors. A. Expression levels of enzymes involved
using qPCR. Data is log2 transformed and normalized to levels of these en
following number of samples: n = 2 (ESCs), n = 3 (Y-iPSCs) and n = 3 (T-iPSCs).
the expected number of genes that are targets of the indicated reprogrammi
binding site. The histograms and box plots represent the null distribution for
and each transcription factor binding sites. The diamonds represent the exper
(C) DNA methylation aberrations and each transcription factor binding sites. R
of the null distribution.Several studies have revealed that many iPSCs that
pass stringent criteria for pluripotency still have non-
random DNA methylation differences as compared to
ESCs which persist during passaging [11,14] and differ-
entiation [14,15]. Incomplete erasure of DNA methyla-
tion marks during the reprogramming of somatic cells
into pluripotent stem cells is thought to underlie theoverlap of aberrantly methylated regions with genomic binding
in methylation and demethylation in pluripotent cells measured
zymes in human fibroblasts. Values shown are the mean of the
B and C. Random sampling simulation to determine the distribution of
ng factor and have aberrant DNA methylation CpGs overlapping the
the overlap between random sampling DNA methylation aberrations
imentally observed number of overlap between Y-iPSCs (B) or T-iPSCs
ed diamonds highlight a number of overlaps that fall completely outside
Table 2 Gene ontology of genes associated with differentially methylated regions
iPS type GO Biological process P-value FDR Q-value Fold enrichment
Y-iPSCs Regulation of glial cell proliferation 5.72 × 10-13 5.01 × 10-9 8.2103
Y-iPSCs Intestinal epithelial cell differentiation 2.98 × 10-11 4.35 × 10-8 10.7333
Y-iPSCs Stem cell development 6.19 × 10-6 9.04 × 10-4 2.247
Y-iPSCs Stem cell maintenance 6.81 × 10-6 9.63 × 10-4 2.2958
T-iPSCs Eye development 3.81 × 10-11 6.68 × 10-8 6.5284
T-iPSCs Spinal cord development 3.68 × 10-9 3.58 × 10-6 2.4715
T-iPSCs Limb bud formation 6.50 × 10-6 1.09 × 10-3 3.1573
GREAT tool [22] was used annotate genes with aberrant methylation in their transcription start site.
Table 1 List of Genes with aberrant promoter DNA methylation
iPSC type Gene name Position relative to
TSS (base pairs)






Y-iPS L1TD1 3887 failure to demethylate SOX2, NANOG 0.205552761
Y-iPS ZNF202 −849 failure to demethylate SOX2, NANOG 0.253028526
Y-iPS VRTN −7 failure to demethylate NANOG 0.204685702
Y-iPS ZNF281 −893 failure to demethylate NANOG 0.217824711
Y-iPS PCBP1-AS1 1655 failure to demethylate NANOG 0.260023778
Y-iPS CELF2 −602 failure to demethylate NANOG 0.201570322
Y-iPS GCLC 2741 failure to demethylate NANOG 0.209894956
Y-iPS CCDC85A −1483 failure to demethylate NANOG 0.231654822
Y-iPS GPC6 −1912 failure to demethylate NANOG 0.2007506
Y-iPS RNF175 1925 failure to demethylate NANOG 0.24800605
Y-iPS LAPTM4B 2519 failure to demethylate NANOG 0.231217277
Y-iPS DUSP5 2071 failure to demethylate NANOG 0.254193033
Y-iPS TDGF1 1259 failure to demethylate NANOG 0.250850333
Y-iPS ZFP36L1 −544 failure to demethylate KLF4 0.310706089
Y-iPS CDC16 −199, −212 spurious methylation OCT4 0.362236745, 0.417741778
Y-iPS ADAR −226 spurious methylation OCT4 0.201398056
Y-iPS RPS23 3852 failure to demethylate OCT4 0.234123761
Y-iPS ZBTB44 −1063, −1044 failure to demethylate OCT4 0.234429233, 0.308618094
Y-iPS KIF3C −433, −422 failure to demethylate OCT4 0.348975978, 0.365098844
Y-iPS HORMAD2 −354, −363 failure to demethylate OCT4 0.233920207, 0.252708599
Y-iPS PSMA8 23 failure to demethylate cMYC 0.238296222
Y-iPS PLEKHG6 −189 failure to demethylate cMYC 0.203390178
T-iPS TNFSF8 −1308 failure to methylate NANOG 0.387689344
T-iPS FLJ31485 3444 failure to demethylate NANOG −0.340429706
T-iPS KCNH2 53 failure to methylate KLF4 0.246395267
T-iPS TMEM132C −365, −905 spurious methylation KLF4, OCT4 −0.327425161,−0.3128155
T-iPS WDR45L −469, −500 failure to methylate OCT4 0.291398672, 0.308650794
T-iPS PABPC1L2A 1760 failure to methylate cMYC 0.272031639
Genes within 5 kilobase window around TSS that were bound by cMYC, OCT4, SOX2, NANOG and KLF4 in human ESCs are shown. TF stands for
transcription factor.
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AB
Figure 5 Cancer versus Normal profile of Y-iPSCs and T-iPSCs aberrantly methylated regions. DNA methylation difference (delta beta
value) between cancer patients and matched normal tissue of each CpG site identified as aberrantly methylated in Y-iPSCs (left panels) or T-iPSCs
(right panels). The DNA methylation data was obtained from the TCGA depository (http://tcga-data.nci.nih.gov) for (A) Colon adenocarcinoma – COAD
(258 tumor samples and 38 normal samples), (B) Head and neck squamous cell carcinoma – HNSC (310 tumor samples and 50 normal samples).
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iPSCs to differentiate into the lineage from which they
were derived, a phenomenon referred to as epigenetic
memory [9-15].
In this study, we observed that despite being generated
from a common parental cell type, the epigenome of
iPSCs harbor distinct DNA methylation aberrations de-
pending on the sets of reprogramming factors used. In
agreement with previous reports, our results also show
that DNA methylation aberrations are dominated by
hypomethylation (62%); however, we have found that a
significant proportion of them are also hypermethylated
as compared to ESCs (32%). Overall, however, we havefound very few instances of aberrant de novo methyla-
tion or demethylation in iPSCs; rather, the vast majority
of the aberrantly methylated sites are result of methyla-
tion and demethylation failure at various sites within the
parental epigenome during reprogramming.
A key finding of our study is that the class of DNA
methylation aberrations in Y-iPSCs and T-iPSCs differ
significantly. Y-iPSCs specific DNA methylation aberra-
tions are mainly characterized by demethylation failure,
suggesting that Yamanaka factor-driven cellular changes
during reprogramming result in deficiency in demethyla-
tion. In contrast, T-iPSCs specific DNA methylation ab-
errations are mainly characterized by DNA methylation
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changes during reprogramming result in deficient DNA
methylation. As the silencing of differentiation genes in
somatic cells is essential for achieving the pluripotent
state [24], the insufficient methylation activity in driven
by the Thomson factors compared to Yamanaka factors
might explain why efficiency of reprogramming with the
former is routinely lower than when using Yamanaka fac-
tors. Given that T-iPSCs are hypomethylated relative to
ESCs and Y-iPSCs are hypermethylated relative to ESCs, it
might be the case that the observed epigenetic memory or
bias of iPSCs to differentiate into parental lineage [10,11],
which is thought to arise due to incomplete silencing of
somatic genes, may be higher in T-iPSCs than in Y-iPSCs.
The differences in methylation and demethylation ac-
tivity during reprogramming (Figure 4A) with Yamanaka
and Thomson reprogramming factors can provide a ra-
tionale for selecting reprogramming factors and reprogram-
ming efficiency-enhancing epigenetic drugs. In particular,
Thomson factors might be a better at reprogramming cell
types that have highly methylated genomes, while the
Yamanaka factors might be better suited for reprogram-
ming of somatic cells that have large proportion of open
chromatin that needs to be silenced during reprogram-
ming. We speculate that reagents that enhance DNA de-
methylation may prove more helpful in overcoming the
failed-type DNA demethylation aberrations in Y-iPSCs re-
programming than in T-iPSCs reprogramming, since the
latter is more efficient in inducing DNA demethylation.
We note that the approach used for DNA methylation
profiling is based on bisulfite conversion and therefore
cannot distinguish between 5-methylcytosine (5-mC) and
5-hydroxymethylcytosine (5-hmC). This means that the
CpGs identified as methylated can either be 5-mC or 5-
hmC. This technical limitation does not invalidate ourFigure 6 Model relating reprogramming factors and types of DNA me
CpGs. White disk represent unmethylated CpG and black disk represent me
proper methylation but failure to demethylate, leading to enrichment of D
reprogramming with the Thomson factors leads to proper demethylation b
aberrations in these iPSCs relative to ESCs.finding that Y-iPSCs aberrations are mainly DNA demeth-
ylation failure. Even if some of the sites classified as de-
methylation failure are actually 5hmC (instead of 5mC),
the same sites are completely unmethylated in T-iPSCs.
Therefore, Y-iPSCs is indeed failing to demethylate these
sites, either by maintaining 5mC or by converting to
5hmC but not been able to further convert to unmethy-
lated cytosine.
In conclusion, our study has revealed that different re-
programming factor combinations lead to differences in
the type and extent of DNA methylation aberrations
observed in iPSCs (Figure 6). It is possible that the
differences in the DNA methylation landscape between
Y-iPSCs and T-iPSCs may lead to subtle phenotypic con-
sequences even when starting with the exact same donor
cell type. We suggest that the differences between T-iPSCs
and Y-iPSCs highlighted above might be advantageously
used for achieving optimal reprogramming of various
donor cell types depending on their overall levels of DNA
methylation of their genome.
Methods and materials
Cell culture
Human neonatal foreskin fibroblasts (ATCC, Manassa,
VA) were cultured in growth medium consisting of
DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% fetal calf serum (Hyclone Laboratories, Mississauga,
ON) and 1 mM L-glutamine (Invitrogen). iPSCs were
maintained on a Matrigel (BD Biosciences, Mississauga,
ON) -coated plate in complete mTeSR1 medium (Stemcell
Technologies, Vancouver, BC) as previously described [25].
Virus production
Four moloney-based retroviral vectors (pMXs) containing the
human complementary DNAs (cDNAs) of OCT4, SOX2,thylation aberrations. A hypothetical genomic region showing four
thylated CpG. Reprogramming with the Yamanaka factors leads to
NA demethylation aberrations in these iPSCs relative to ESCs. Similarly,
ut failure to methylate, leading to enrichment of DNA methylation
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Addgene (Cambridge, MA). These plasmids were trans-
fected into the 293GPG packaging cell line that incorpo-
rated pMD.gagpol and tetracycline-inducible VSV-G
plasmids to generate high titer retroviruses as previously
described [26]. Viral supernatant was collected 48, 72 and
96 hours post-transfection and filtered by 0.45 μm syringe
filters.
Generation of iPSCs
iPSCs were generated as previously described [16]. Briefly,
4 × 105 fibroblasts were seeded in gelatin-coated 100 mm
dishes in fibroblast medium and were infected twice by
OCT4, SOX2, KLF4 and cMYC or OCT4, SOX2, NANOG
and LIN28 transgene containing retroviruses during a
48 hours period after seeding fibroblasts. Approximately
24 hours after second viral infection, cells were switched to
ESC media consisting of knockout DMEM supplemented
with 20% knockout serum replacement, 1 mM L-glutam-
ine, 1% non-essential amino acid, 0.1 mM ß-mercaptoetha-
nol and 10 ng/ml human basic fibroblast growth factor
(bFGF; Invitrogen). Approximately 3 to 4 weeks post-
infection, newly formed colonies with ESC-like morph-
ology were picked.
DNA methylation profiling
Genomic DNA samples (1 ug each) were bisulfite con-
verted using the Zymo EZ DNA methylation kit (Zymo
Research, Orange, CA, USA; catalog #D5002) according
to the manufacturer’s instructions. All cell lines passed bi-
sulfite conversion quality control and were subsequently
processed for the Illumina Infinium DNA methylation
platform (HumanMethylation450 BeadChip). A beta value
(β) of 0–1.0 was reported for each CpG site (methylation
ranging from 0% to 100%, respectively). β values were
calculated by subtracting background and taking the ratio
of the methylated signal intensity to the sum of both
unmethylated (U) and methylated (M) signals: M/(M+U).
The McGill University Genome Quebec Innovation
Centre in Montreal performed the Infinium methylation
assays in accordance with the manufacturer’s instruc-
tions. The assay information is available at http://www.
illumina.com. The Infinium array cover 482,421 CpG
sites of approximately 28 million sites in the human gen-
ome and covers 99% of RefSeq genes, averaging 17 CpG
sites per gene. It covers 96% of human CpG islands, with
additional coverage in island shores and the regions
flanking them.
Preprocessing of Illumina HumanMethylation450 data
Data were normalized and background corrected using
GenomeStudio. Briefly, the red and green signals were
normalized by multiplying the green signal by the product
of the red channel control value divided by the greenchannel control value. Control values were obtained from
the control profile file. Background subtraction was per-
formed from both channels using the negative probe con-
trol values.
Identification of differentially methylated CpGs
To identify differentially methylated CpGs in iPSCs, we
used a well-accepted method and threshold [27,28]. We
calculated the DNA methylation difference and FDR-
corrected Wilcoxon signed-rank test of differences be-
tween ESCs and iPSCs. We established a DNA methy-
lation difference of more than 0.2 or less than −0.2 and an
FDR-corrected p-value lower than 0.05 as a threshold to
define a differentially methylated probe (Additional file 1:
Figure S3). In addition, to identifying whether each of the
differentially methylated CpGs in iPSCs falls under each
theoretical class DNA methylation aberration, we divided
the CpGs in 4 groups: 1) heavily methylated in ESCs
and fibroblasts; 2) heavily unmethylated in ESCs and fi-
broblasts; 3) significantly hypomethylated in fibroblasts
compared to ESCs; and 4) significantly hypermethylated
in fibroblasts compared to ESCs. Statistical significance
of the CpGs was evaluated using 9 independent Y-iPSCs
and 6 independent T-iPSCs, all generated from the
same batch of fibroblasts. Significant differences in
DNA methylation levels in Y-iPSCs and T-iPSCs were
determined for each probe using Wilcoxon rank sum
test followed by an FDR correction, using the Benjamini
and Hochberg approach, in order to correct for multiple
tests. The raw p-value and the FDR-corrected p-value
were calculated for all CpGs in the assay and presented
as a Density Volcano Plot. The mean beta value across
each group was computed and then subtracting from
the beta value of each probe to generate the beta value
difference between the two groups. All the statistical
tests were performed in Matlab using the statistical and
bioinformatics toolboxes.
Computation of enrichment of aberrations at regions
bound by reprogramming factors in ESCs
We then used permutation testing (10,000 permutations,
without replacement) to generate null distributions from
randomized differentially methylated CpGs (aberrant in
T-iPSCs or aberrant in Y-iPSCs) across all the CpGs in
the array. We then counted how many times each of this
random null distribution overlaps with the experimen-
tally ascertained transcription factor-binding peaks and
calculated the exact permutation p-values [29].
Reduced Representation Bisulfite Sequencing (RRBS)
RRBS was performed according to a previously pub-
lished protocol [30,31] with the following modifications:
15 ng of genomic DNA from Y-iPSCs and T-iPSCs was
the initial input for MSPI digestion. For ligation step the
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1:4 and 1.5 μl added in the reaction. The incubation time
for ligation was 24 hours. For the first amplification step,
after bisulfite conversion and before fragment selection,
reaction was performed in 25 μl containing 1x Kapa HiFi
HotStart Uracil + Ready mix (MA, USA), 3 μl of Cocktail
PCR primer (TruSeq kit) and 8 μl of bisulfite converted
DNA (Sigma). The amplification program consisted of
an initial denaturation step at 98°C during 45 seconds and
6 cycles of: 15 seconds at 98°C, 30 seconds at 60°C, 30 sec-
onds at 72°C, and a final elongation step of 1 minute at
72°C. Fragment size selection was performed with 3%
Nusieve 3:1 agarose 0.5x TBE gel and the gel ladder was
stained with 1:20,000 dilution of RedSafe (Chembio, UK).
The gel was cut between 150 and 400 base pairs. Gel ex-
traction was performed with Qiagen Minelute kit in 2 col-
umns and eluted in 10 μl each. Final library was prepared
in 50 μl containing 1 μl of Kapa Hifi HotStart DNA poly-
merase (1U/μl) (Kapa biosystems, MA, USA), 10 μl of 5×
Kapa HiFi fidelity Buffer, 1.5 μl of Kapa dNTP mix (10 nm
each), 6 μl of TruSeq Cocktail PCR primer and 20 μl of
size selected DNA fragments. The amplification program
consisted of an initial denaturation step at 95°C during
2 minutes and 12 cycles of: 20 seconds at 98°C, 30 seconds
at 60°C, 30 seconds at 72°C, and a final elongation
step of 1 minute at 72°C. The final library was purified
using Agencourt AMpure XP magnetic beads (Beckman
Coulter) according to the manufacturer’s protocol.
Comparison of Illumina HumanMethylation450 and
sequencing based DNA methylation profiles
In RRBS, DNA is digested with Msp1 restriction enzyme
(which is methylation insensitive) and 200 to 400 pair
fragments are extracted, bisulfite converted and se-
quenced. The sequence reads were aligned to the gen-
ome using the Novoalign (http://novocraft.com) aligner
(onto the in silico converted genome reference) and only
uniquely aligning reads were retained. Methylation levels
at CpG with a minimum of 5-fold coverage were com-
puted. RRBS computed methylation levels and Illumina
HumanMethylation450 methylation levels can be com-
pared directly and without normalization because both
methods measure absolute DNA methylation levels. For
a total of 2,710 single CpGs that were covered by both
an Illumina HumanMethylation450 probe and at least
five RRBS reads in Y-iPSCs, we observed a Pearson
correlation of 0.79 (Additional file 1: Figure S2). For
T-iPSCs, we obtained a total of 2,398 single CpGs that
were covered by both methods and a Pearson correlation
of 0.81 (Additional file 1: Figure S2).
RNA extraction
RNA was purified from parental fibroblasts, Y-iPSCs, T-iPSCs,
and ESCs using Trizol (Invitrogen, CA, USA) protocol. UsingSuperScript III (Invitrogen) 2 μg of RNA were taken to
RT reaction in a final volume of 20 μl. The cDNA was di-
luted to a final volume of 50 μl and 1 μl was used for the
qPCR.
qPCR conditions
All qPCR reactions were carried out in an Applied Bio-
systems One Step thermal cycler (CA, USA). The reac-
tions were performed in 20 μl final volume containing
1 × SYBR Select Mastermix (Applied Biosystems CA,
USA), primers at concentration of 250 nM. The reac-
tions were performed in experimental and biological tripli-
cate. The amplification program consisted of an initial
denaturation step at 95°C during 5 minutes and 40 cycles
of: 20 seconds at 95°C, 30 seconds at 60°C, 45 seconds at
72°C, and a final elongation step of 1 minute at 72°C. After
the amplification protocol, melting curves were performed
in order to analyze the specificity of the amplified frag-
ments, by measuring fluorescence signal at increment-
ing temperatures of 0.3°C, from 65°C to 95°C. The internal
control was GAPDH gene.
Data availability
The Illumina HumanMethylation450 is available online
at Gene Expression Omnibus (http://www.ncbi.nlm.nih.
gov/geo/) accession number GSE54115.Additional files
Additional file 1: Characterization of iPS lines used in the paper.
(A) Phase contrast images showing colony morphology for all the Y-iPS
(OSKM) and T-iPS (OSLN) lines used in this study. All iPS cells were stably
maintainable in culture till passage 12 (after which they were frozen).
Scale bar, 350 μm. (B) qPCR analysis of pluripotency markers. Figure S2.
Validation of Illumina Infinium HumanMethylation450 platform by Reduced
Representation Bisulfite Sequencing (RRBS). Correlation between the DNA
methylation levels accessed by HumanMethylation450 and RRBS in a Y-iPS
(A) and a T-iPS (B) sample. Figure S3. The beta value difference in DNA
methylation between iPS cells and ES cells is plotted on the x axis, and the
p value for a FDR-corrected Wilcoxon signed-rank test of differences
between iPS cells and ES cells is plotted on the y axis. Figure S4. Observed
versus expected ratio for the four classes of aberrations to the DNA
methylation pattern. Figure S5. Observed versus expected ratio for
the position relative to a CpG Island of each class of aberrations to the
DNA methylation pattern. (A) Schematic distribution of CpG islands,
shores, shelfs and open sea. Ratio between the observed number of
CpGs in the spurious demethylation class (B), spurious methylation
class (C), failure to methylate class (D), failure to demethylate class (E) versus
the randomly expected number of CpGs. Figure S6. Region-Gene association
graph for the position relative to a TSS of T-iPS and Y-iPS-specific aberrations.
(A) Y-iPS specific aberrations. (B) T-iPS specific aberrations. Figure S7. Cancer
versus Normal profile of Y-iPS and T-iPS aberrantly methylated regions. DNA
methylation difference between cancer patients and matched normal tissue
of each CpG site identified as aberrantly methylated in Y-iPS cells (left panels)
or T-iPS cells (right panels). The DNA methylation data was obtained
from the TCGA depository (http://tcgadata. nci.nih.gov) for (A) Bladder
Urothelial Carcinoma – BLCA (171 tumor samples and 19 normal samples),
(B) Breast invasive carcinoma – BRCA (613 tumor samples and 97 normal
samples), (C) Lung adenocarcinoma – LUAD (409 tumor samples and 32
normal samples) and (D) Lung squamous cell carcinoma – LUSC (252 tumor
samples and 42 normal samples).
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methylated between Y-iPS and T-iPS.
Additional file 3: List of genomic binding sites of reprogramming
factors in H1 ES cells that overlap with aberrantly methylated
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